Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial

202334 citationsJournal Articlegreen Open Access

Authors

Jeff M. Michalski · Washington University in St. Louis

Kathryn Winter · NRG Oncology

Bradley R. Prestidge · Bon Secours DePaul Medical Center

Martin G. Sanda · Emory University Hospital

Mahul B. Amin · University of Tennessee Health Science Center

William S. Bice · John Muir Medical Center

Hiram A. Gay

Abstract

Compared with BT, COMBO did not improve FFP for prostate cancer but caused greater toxicity. BT alone can be considered as a standard treatment for men with intermediate-risk prostate cancer.

Topics & Keywords

Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Advanced Radiotherapy Techniques

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 41, Issue 24, pp. 4035-4044

DOI: 10.1200/jco.22.01856

Field-Weighted Citation Impact: 8.84